Ocular Therapeutix Enrolls First Patient in Axpali Long-Term Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy OCUL?
Ocular Therapeutix announced that the first patient has been enrolled in the SOL-X long-term extension trial for Axpali for the treatment of wet age-related macular degeneration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCUL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCUL
Wall Street analysts forecast OCUL stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.680
Low
20.00
Averages
23.43
High
31.00
Current: 9.680
Low
20.00
Averages
23.43
High
31.00
About OCUL
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ocular Therapeutix Q1 2026 Earnings Call Insights
- Clinical Trial Breakthrough: Ocular Therapeutix's SOL-1 Phase III trial results indicate that AXPAXLI is the first investigational therapy to surpass an approved anti-VEGF agent in treating wet AMD, with 2/3 of patients maintaining vision for an entire year after just one injection, marking a significant advancement in the treatment landscape.
- Regulatory Pathway Planning: The company intends to submit a New Drug Application (NDA) based on SOL-1 Week 52 data and plans to leverage the 505(b)(2) pathway to shorten review timelines, a strategy that will accelerate the commercialization process for AXPAXLI.
- Strong Financial Position: As of Q1 2026, the company reported approximately $667 million in cash, expected to sustain operations into 2028, although management cautioned that this does not cover all expenses anticipated for AXPAXLI's commercialization.
- Future Outlook: Management anticipates releasing SOL-R top-line data in Q1 2027 and plans to provide detailed updates on the NDA submission strategy and commercialization plans during the Investor Day on June 17, reflecting the company's confidence in future growth.
See More
Ocular Therapeutix to Announce Q1 Earnings on May 5th
- Earnings Announcement Date: Ocular Therapeutix (OCUL) is set to announce its Q1 earnings on May 5th before market open, with a consensus EPS estimate of -$0.32, reflecting a 15.8% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $12.7 million, representing an 18.7% year-over-year increase, which highlights a positive trend in market demand and product sales, despite facing certain challenges.
- Historical Performance Review: Over the past two years, OCUL has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating volatility in financial forecasting that may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, there has been one upward revision in EPS estimates with no downward revisions, while revenue estimates have seen four downward revisions, suggesting a weakening market outlook for the company’s future revenue growth, which could impact stock performance.
See More
Ocular Therapeutix to Participate in Multiple Conferences
- Investor Conference Schedule: Ocular Therapeutix is set to participate in the Bank of America Health Care Conference on May 12, 2026, in Las Vegas, where Executive Chairman Pravin U. Dugel, MD, will engage in a 30-minute fireside chat, likely enhancing investor interest and company visibility.
- Scientific Conference Presentations: The company will showcase its theme of 'Redefining the Retina Experience' at the Eyecelerator @ ARVO conference on May 1, 2026, which is expected to bolster its influence in the retinal disease sector.
- Clinical Trial Progress: Ocular's AXPAXLI™ (OTX-TKI) is currently undergoing Phase 3 clinical trials for wet age-related macular degeneration and diabetic retinal disease, with successful advancement potentially strengthening the company's future market competitiveness.
- Diverse Product Pipeline: In addition to AXPAXLI, Ocular is also developing DEXTENZA® and OTX-TIC, the latter of which has completed Phase 2 clinical trials, demonstrating the company's broad positioning and ongoing innovation in the ophthalmic treatment landscape.
See More
AXPAXLI Demonstrates Unmatched Durability in Wet AMD Treatment
- Clinical Trial Results: In the SOL-1 Phase 3 trial, 74.1% of subjects maintained vision at Week 36 with AXPAXLI, a 17.5% improvement over the aflibercept group, highlighting its significant efficacy in wet AMD treatment.
- Disease Control Capability: The median time to achieve a ≥30 uM increase in Central Subfield Thickness (CSFT) from Week 8 to Week 52 was 39 weeks for the AXPAXLI group, compared to 16 weeks for the aflibercept group, indicating a 23-week advantage in disease control.
- Sustained Visual Outcomes: At Week 52, AXPAXLI subjects showed an average improvement of +11.8 ETDRS letters in visual acuity, significantly higher than the +8.5 letters in the aflibercept group, demonstrating consistent effectiveness across different baseline vision quartiles.
- Good Safety Profile: Among all AXPAXLI subjects with vitreous floaters, drug particles were no longer visible after an average of 20 weeks, indicating a favorable safety profile that does not impair vision, thereby enhancing confidence in clinical adoption.
See More
Ocular Therapeutix Shares Surge 10.45% Ahead of Key Conferences
- Stock Surge: Ocular Therapeutix shares rose 10.45% on Thursday, closing at $9.30, reflecting strong investor anticipation for upcoming business updates, particularly from key presentations at several conferences.
- Key Conference Participation: Chief Scientific Officer Jeffrey Heier and Chief Development Officer Peter Kaiser are set to speak at the 14th Annual Vit-Buckle Society Meeting in Las Vegas on April 11, discussing management strategies for Neovascular AMD, which could influence the company's future treatment directions.
- CEO Presentation: Chairman and CEO Pravin Dugel will present at the Congreso Nacional de Oftalmologia in Buenos Aires on April 15, covering Tyrosine Kinase Inhibitors and the current state of treatments for diabetic retinal disease, likely drawing investor interest.
- Clinical Trial Progress: Investors are keenly awaiting updates on Ocular Therapeutix's investigational drug Axpaxli, currently in a phase 3 trial for wet AMD and non-proliferative diabetic retinopathy, with potential implications for stock price movement following the conferences.
See More
Ocular Therapeutix to Participate in Multiple Scientific Conferences
- Conference Participation: Ocular Therapeutix is set to participate in several scientific conferences in April 2026, showcasing its advancements in wet age-related macular degeneration (wet AMD), which is expected to enhance its influence in the ophthalmic biopharmaceutical sector.
- VBS Conference Presentation: At the 14th Annual Vit-Buckle Society Meeting from April 9-11, Ocular will present additional data from the SOL-1 Phase 3 clinical trial on April 11, further solidifying its leadership in managing neovascular AMD.
- CNO 2026 Engagement: Ocular will also deliver multiple presentations at the Congreso Nacional de Oftalmologia 2026 from April 15-17, covering the role of TKIs and the current state of diabetic retinal disease treatment, demonstrating its expertise in ocular therapies.
- Pipeline Updates: AXPAXLI™ (OTX-TKI) is currently in Phase 3 trials, and Ocular is evaluating next steps for other products like OTX-TIC, reflecting the company's ongoing commitment to innovation in ocular treatments.
See More
Ocular Therapeutix Q1 2026 Earnings Call Insights
- Clinical Trial Breakthrough: Ocular Therapeutix's SOL-1 Phase III trial results indicate that AXPAXLI is the first investigational therapy to surpass an approved anti-VEGF agent in treating wet AMD, with 2/3 of patients maintaining vision for an entire year after just one injection, marking a significant advancement in the treatment landscape.
- Regulatory Pathway Planning: The company intends to submit a New Drug Application (NDA) based on SOL-1 Week 52 data and plans to leverage the 505(b)(2) pathway to shorten review timelines, a strategy that will accelerate the commercialization process for AXPAXLI.
- Strong Financial Position: As of Q1 2026, the company reported approximately $667 million in cash, expected to sustain operations into 2028, although management cautioned that this does not cover all expenses anticipated for AXPAXLI's commercialization.
- Future Outlook: Management anticipates releasing SOL-R top-line data in Q1 2027 and plans to provide detailed updates on the NDA submission strategy and commercialization plans during the Investor Day on June 17, reflecting the company's confidence in future growth.
See More
Ocular Therapeutix to Announce Q1 Earnings on May 5th
- Earnings Announcement Date: Ocular Therapeutix (OCUL) is set to announce its Q1 earnings on May 5th before market open, with a consensus EPS estimate of -$0.32, reflecting a 15.8% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $12.7 million, representing an 18.7% year-over-year increase, which highlights a positive trend in market demand and product sales, despite facing certain challenges.
- Historical Performance Review: Over the past two years, OCUL has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating volatility in financial forecasting that may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, there has been one upward revision in EPS estimates with no downward revisions, while revenue estimates have seen four downward revisions, suggesting a weakening market outlook for the company’s future revenue growth, which could impact stock performance.
See More
Ocular Therapeutix to Participate in Multiple Conferences
- Investor Conference Schedule: Ocular Therapeutix is set to participate in the Bank of America Health Care Conference on May 12, 2026, in Las Vegas, where Executive Chairman Pravin U. Dugel, MD, will engage in a 30-minute fireside chat, likely enhancing investor interest and company visibility.
- Scientific Conference Presentations: The company will showcase its theme of 'Redefining the Retina Experience' at the Eyecelerator @ ARVO conference on May 1, 2026, which is expected to bolster its influence in the retinal disease sector.
- Clinical Trial Progress: Ocular's AXPAXLI™ (OTX-TKI) is currently undergoing Phase 3 clinical trials for wet age-related macular degeneration and diabetic retinal disease, with successful advancement potentially strengthening the company's future market competitiveness.
- Diverse Product Pipeline: In addition to AXPAXLI, Ocular is also developing DEXTENZA® and OTX-TIC, the latter of which has completed Phase 2 clinical trials, demonstrating the company's broad positioning and ongoing innovation in the ophthalmic treatment landscape.
See More
AXPAXLI Demonstrates Unmatched Durability in Wet AMD Treatment
- Clinical Trial Results: In the SOL-1 Phase 3 trial, 74.1% of subjects maintained vision at Week 36 with AXPAXLI, a 17.5% improvement over the aflibercept group, highlighting its significant efficacy in wet AMD treatment.
- Disease Control Capability: The median time to achieve a ≥30 uM increase in Central Subfield Thickness (CSFT) from Week 8 to Week 52 was 39 weeks for the AXPAXLI group, compared to 16 weeks for the aflibercept group, indicating a 23-week advantage in disease control.
- Sustained Visual Outcomes: At Week 52, AXPAXLI subjects showed an average improvement of +11.8 ETDRS letters in visual acuity, significantly higher than the +8.5 letters in the aflibercept group, demonstrating consistent effectiveness across different baseline vision quartiles.
- Good Safety Profile: Among all AXPAXLI subjects with vitreous floaters, drug particles were no longer visible after an average of 20 weeks, indicating a favorable safety profile that does not impair vision, thereby enhancing confidence in clinical adoption.
See More
Ocular Therapeutix Shares Surge 10.45% Ahead of Key Conferences
- Stock Surge: Ocular Therapeutix shares rose 10.45% on Thursday, closing at $9.30, reflecting strong investor anticipation for upcoming business updates, particularly from key presentations at several conferences.
- Key Conference Participation: Chief Scientific Officer Jeffrey Heier and Chief Development Officer Peter Kaiser are set to speak at the 14th Annual Vit-Buckle Society Meeting in Las Vegas on April 11, discussing management strategies for Neovascular AMD, which could influence the company's future treatment directions.
- CEO Presentation: Chairman and CEO Pravin Dugel will present at the Congreso Nacional de Oftalmologia in Buenos Aires on April 15, covering Tyrosine Kinase Inhibitors and the current state of treatments for diabetic retinal disease, likely drawing investor interest.
- Clinical Trial Progress: Investors are keenly awaiting updates on Ocular Therapeutix's investigational drug Axpaxli, currently in a phase 3 trial for wet AMD and non-proliferative diabetic retinopathy, with potential implications for stock price movement following the conferences.
See More
Ocular Therapeutix to Participate in Multiple Scientific Conferences
- Conference Participation: Ocular Therapeutix is set to participate in several scientific conferences in April 2026, showcasing its advancements in wet age-related macular degeneration (wet AMD), which is expected to enhance its influence in the ophthalmic biopharmaceutical sector.
- VBS Conference Presentation: At the 14th Annual Vit-Buckle Society Meeting from April 9-11, Ocular will present additional data from the SOL-1 Phase 3 clinical trial on April 11, further solidifying its leadership in managing neovascular AMD.
- CNO 2026 Engagement: Ocular will also deliver multiple presentations at the Congreso Nacional de Oftalmologia 2026 from April 15-17, covering the role of TKIs and the current state of diabetic retinal disease treatment, demonstrating its expertise in ocular therapies.
- Pipeline Updates: AXPAXLI™ (OTX-TKI) is currently in Phase 3 trials, and Ocular is evaluating next steps for other products like OTX-TIC, reflecting the company's ongoing commitment to innovation in ocular treatments.
See More
